Galena starts pivotal PhIII with NeuVax to fill Herceptin gap in breast cancer
This article was originally published in Scrip
Executive Summary
Galena Biopharma remains on track for advancing its lead product, the cancer immunotherapy NeuVax (a HER2-derived E75 peptide plus GM-CSF vaccine), as it has begun dosing the first patients for its randomised, double-blind, multicentre PRESENT Phase III trial, to prevent breast cancer recurrence using NeuVax as an additional therapy.